speb/financial-data huggingface dataset:
BABY.TO balance_sheet (annual, 2023-12-31) — Retained Earnings: -64477000.00
BABY.TO income_statement (annual, 2023-12-31) — Salaries And Wages: 5177000.00
BABY.TO income_statement (annual, 2023-12-31) — Selling And Marketing Expense: 4378000.00
BABY.TO income_statement (annual, 2023-12-31) — Selling General And Administration: 11652000.00
BABY.TO balance_sheet (annual, 2023-12-31) — Share Issued: 136094159.00
BABY.TO cash_flow (annual, 2023-12-31) — Stock Based Compensation: 353000.00
BABY.TO balance_sheet (annual, 2023-12-31) — Stockholders Equity: 6721000.00
BABY.TO balance_sheet (annual, 2023-12-31) — Tangible Book Value: 6528000.00
BABY.TO income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: 0.00
BABY.TO income_statement (annual, 2023-12-31) — Tax Rate For Calcs: 0.00
BABY.TO balance_sheet (annual, 2023-12-31) — Total Assets: 16069000.00
BABY.TO balance_sheet (annual, 2023-12-31) — Total Capitalization: 7074000.00
BABY.TO balance_sheet (annual, 2023-12-31) — Total Debt: 3091000.00
BABY.TO balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: 6721000.00
BABY.TO income_statement (annual, 2023-12-31) — Total Expenses: 26372000.00
BABY.TO balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 9348000.00
BABY.TO balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 942000.00
BABY.TO balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 462000.00
BABY.TO income_statement (annual, 2023-12-31) — Total Unusual Items: 3934000.00
BABY.TO income_statement (annual, 2023-12-31) — Total Unusual Items Excluding Goodwill: 3934000.00
BABY.TO balance_sheet (annual, 2023-12-31) — Work In Process: 830000.00
BABY.TO balance_sheet (annual, 2023-12-31) — Working Capital: 6241000.00
BABY.TO income_statement (quarterly, 2024-09-30) — Basic Average Shares: 16786551.00
BABY.TO income_statement (quarterly, 2024-09-30) — Basic EPS: -0.14
BABY.TO income_statement (quarterly, 2024-09-30) — Diluted Average Shares: 16786551.00
BABY.TO income_statement (quarterly, 2024-09-30) — Diluted EPS: -0.14
BABY.TO balance_sheet (quarterly, 2024-09-30) — Long Term Capital Lease Obligation: 0.00
BABY.TO balance_sheet (quarterly, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 0.00
BABY.TO cash_flow (quarterly, 2024-09-30) — Long Term Debt Issuance: 0.00
BABY.TO balance_sheet (quarterly, 2024-09-30) — Other Short Term Investments: 0.00
BABY.TO income_statement (annual, 2024-12-31) — +Operating Expense: 13555000.00
BABY.TO income_statement (annual, 2024-12-31) — +Total Revenue: 7973000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Accounts Payable: 2836000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Accounts Receivable: 833000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Accumulated Depreciation: -399000.00
BABY.TO balance_sheet (quarterly, 2024-12-31) — Accumulated Depreciation: -399000.00
BABY.TO income_statement (annual, 2024-12-31) — Basic Average Shares: 16770863.00
BABY.TO income_statement (annual, 2024-12-31) — Basic EPS: -0.09
BABY.TO cash_flow (annual, 2024-12-31) — Beginning Cash Position: 2931000.00
BABY.TO cash_flow (annual, 2024-12-31) — Capital Expenditure: -62000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Capital Lease Obligations: 135000.00
BABY.TO balance_sheet (quarterly, 2024-12-31) — Capital Lease Obligations: 135000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Capital Stock: 73413000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 103000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 103000.00
BABY.TO cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Financing Activities: 3730000.00
BABY.TO cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Investing Activities: 2708000.00
BABY.TO cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Operating Activities: -9058000.00
BABY.TO cash_flow (annual, 2024-12-31) — Change In Account Payable: 938000.00
BABY.TO cash_flow (annual, 2024-12-31) — Change In Inventory: 2575000.00
BABY.TO cash_flow (annual, 2024-12-31) — Change In Payable: 1598000.00
BABY.TO cash_flow (annual, 2024-12-31) — Change In Payables And Accrued Expense: 1598000.00
BABY.TO cash_flow (annual, 2024-12-31) — Change In Receivables: 714000.00
BABY.TO cash_flow (annual, 2024-12-31) — Change In Working Capital: 4887000.00
BABY.TO cash_flow (annual, 2024-12-31) — Changes In Account Receivables: 579000.00
BABY.TO cash_flow (annual, 2024-12-31) — Changes In Cash: -2620000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Common Stock: 73413000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Common Stock Equity: 1755000.00
BABY.TO cash_flow (annual, 2024-12-31) — Common Stock Issuance: 2478000.00
BABY.TO income_statement (annual, 2024-12-31) — Cost Of Revenue: 9135000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Current Accrued Expenses: 2023000.00
BABY.TO balance_sheet (quarterly, 2024-12-31) — Current Accrued Expenses: 2023000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Current Assets: 6843000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Current Capital Lease Obligation: 135000.00
BABY.TO balance_sheet (quarterly, 2024-12-31) — Current Capital Lease Obligation: 135000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Current Debt: 739000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Current Debt And Capital Lease Obligation: 874000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Current Liabilities: 5805000.00
BABY.TO cash_flow (annual, 2024-12-31) — Depreciation Amortization Depletion: 336000.00
BABY.TO income_statement (annual, 2024-12-31) — Depreciation Amortization Depletion Income Statement: 336000.00
BABY.TO cash_flow (annual, 2024-12-31) — Depreciation And Amortization: 336000.00
BABY.TO income_statement (annual, 2024-12-31) — Depreciation And Amortization In Income Statement: 336000.00
BABY.TO income_statement (annual, 2024-12-31) — Diluted Average Shares: 16770863.00
BABY.TO income_statement (annual, 2024-12-31) — Diluted EPS: -0.09
BABY.TO income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: -15182000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Dueto Related Parties Current: 28000.00
BABY.TO income_statement (annual, 2024-12-31) — EBIT: -15114000.00
BABY.TO income_statement (annual, 2024-12-31) — EBITDA: -14778000.00
BABY.TO cash_flow (annual, 2024-12-31) — Effect Of Exchange Rate Changes: -264000.00
BABY.TO cash_flow (annual, 2024-12-31) — End Cash Position: 47000.00
BABY.TO cash_flow (annual, 2024-12-31) — Financing Cash Flow: 3730000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Finished Goods: 3262000.00
BABY.TO balance_sheet (quarterly, 2024-12-31) — Finished Goods: 3262000.00
BABY.TO cash_flow (annual, 2024-12-31) — Free Cash Flow: -9120000.00
BABY.TO cash_flow (annual, 2024-12-31) — Gain Loss On Investment Securities: -2545000.00
BABY.TO income_statement (annual, 2024-12-31) — Gain On Sale Of Ppe: 0.00
BABY.TO income_statement (annual, 2024-12-31) — Gain On Sale Of Security: 2678000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Gains Losses Not Affecting Retained Earnings: 67000.00
BABY.TO income_statement (annual, 2024-12-31) — General And Administrative Expense: 5654000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Goodwill: 50000.00
BABY.TO balance_sheet (quarterly, 2024-12-31) — Goodwill: 50000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Goodwill And Other Intangible Assets: 164000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Gross PPE: 952000.00
BABY.TO income_statement (annual, 2024-12-31) — Gross Profit: -1162000.00
BABY.TO income_statement (annual, 2024-12-31) — Interest Expense: 68000.00
BABY.TO income_statement (annual, 2024-12-31) — Interest Expense Non Operating: 68000.00
BABY.TO income_statement (annual, 2024-12-31) — Interest Income: 78000.00
BABY.TO income_statement (annual, 2024-12-31) — Interest Income Non Operating: 78000.00
BABY.TO cash_flow (annual, 2024-12-31) — Interest Paid Cfo: 0.00
BABY.TO balance_sheet (annual, 2024-12-31) — Inventory: 5122000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Invested Capital: 2494000.00
BABY.TO cash_flow (annual, 2024-12-31) — Investing Cash Flow: 2708000.00
BABY.TO cash_flow (annual, 2024-12-31) — Issuance Of Capital Stock: 2478000.00
BABY.TO cash_flow (annual, 2024-12-31) — Issuance Of Debt: 1299000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Leases: 73000.00
BABY.TO balance_sheet (quarterly, 2024-12-31) — Leases: 73000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Line Of Credit: 56000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Long Term Capital Lease Obligation: 0.00
BABY.TO balance_sheet (quarterly, 2024-12-31) — Long Term Capital Lease Obligation: 0.00
BABY.TO balance_sheet (annual, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 0.00
BABY.TO balance_sheet (quarterly, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 0.00
BABY.TO cash_flow (annual, 2024-12-31) — Long Term Debt Issuance: 1299000.00
BABY.TO cash_flow (quarterly, 2024-12-31) — Long Term Debt Issuance: 0.00
BABY.TO cash_flow (annual, 2024-12-31) — Long Term Debt Payments: -228000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Machinery Furniture Equipment: 286000.00
BABY.TO balance_sheet (quarterly, 2024-12-31) — Machinery Furniture Equipment: 286000.00
BABY.TO cash_flow (annual, 2024-12-31) — Net Common Stock Issuance: 2478000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Net Debt: 636000.00
BABY.TO income_statement (annual, 2024-12-31) — Net Income: -15182000.00
BABY.TO income_statement (annual, 2024-12-31) — Net Income Common Stockholders: -15182000.00
BABY.TO income_statement (annual, 2024-12-31) — Net Income Continuous Operations: -15182000.00
BABY.TO income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: -15182000.00
BABY.TO income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: -15182000.00
BABY.TO cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: -15182000.00
BABY.TO income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: -15182000.00
BABY.TO income_statement (annual, 2024-12-31) — Net Interest Income: 10000.00
BABY.TO cash_flow (annual, 2024-12-31) — Net Investment Purchase And Sale: 2063000.00
BABY.TO cash_flow (quarterly, 2024-12-31) — Net Investment Purchase And Sale: 19000.00
BABY.TO cash_flow (annual, 2024-12-31) — Net Issuance Payments Of Debt: 1071000.00
BABY.TO cash_flow (annual, 2024-12-31) — Net Long Term Debt Issuance: 1071000.00
BABY.TO income_statement (annual, 2024-12-31) — Net Non Operating Interest Income Expense: 10000.00
BABY.TO cash_flow (annual, 2024-12-31) — Net Other Investing Changes: 707000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Net PPE: 553000.00
BABY.TO cash_flow (annual, 2024-12-31) — Net PPE Purchase And Sale: -62000.00
BABY.TO cash_flow (annual, 2024-12-31) — Net Short Term Debt Issuance: 0.00
BABY.TO balance_sheet (annual, 2024-12-31) — Net Tangible Assets: 1591000.00
BABY.TO income_statement (annual, 2024-12-31) — Normalized EBITDA: -17456000.00
BABY.TO income_statement (annual, 2024-12-31) — Normalized Income: -17860000.00
BABY.TO cash_flow (annual, 2024-12-31) — Operating Cash Flow: -9058000.00
BABY.TO cash_flow (annual, 2024-12-31) — Operating Gains Losses: -2545000.00
BABY.TO income_statement (annual, 2024-12-31) — Operating Income: -14717000.00
BABY.TO income_statement (annual, 2024-12-31) — Operating Revenue: 7973000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 228854107.00
BABY.TO balance_sheet (annual, 2024-12-31) — Other Current Borrowings: 683000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Other Current Liabilities: 44000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Other Equity Adjustments: 67000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Other Equity Interest: 7934000.00
BABY.TO income_statement (annual, 2024-12-31) — Other Gand A: 1508000.00
BABY.TO income_statement (annual, 2024-12-31) — Other Income Expense: -475000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Other Intangible Assets: 114000.00
BABY.TO balance_sheet (quarterly, 2024-12-31) — Other Intangible Assets: 114000.00
BABY.TO cash_flow (annual, 2024-12-31) — Other Non Cash Items: 3210000.00
BABY.TO income_statement (annual, 2024-12-31) — Other Non Operating Income Expenses: -3153000.00
BABY.TO income_statement (annual, 2024-12-31) — Other Operating Expenses: 1757000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Other Properties: 593000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Other Receivables: 256000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Other Short Term Investments: 0.00
BABY.TO balance_sheet (quarterly, 2024-12-31) — Other Short Term Investments: 0.00
BABY.TO balance_sheet (annual, 2024-12-31) — Payables: 2864000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Payables And Accrued Expenses: 4887000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Prepaid Assets: 233000.00
BABY.TO balance_sheet (quarterly, 2024-12-31) — Prepaid Assets: 233000.00
BABY.TO income_statement (annual, 2024-12-31) — Pretax Income: -15182000.00
BABY.TO cash_flow (annual, 2024-12-31) — Proceeds From Stock Option Exercised: 181000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Properties: 0.00
BABY.TO balance_sheet (quarterly, 2024-12-31) — Properties: 0.00
BABY.TO cash_flow (annual, 2024-12-31) — Purchase Of PPE: -62000.00
BABY.TO cash_flow (quarterly, 2024-12-31) — Purchase Of PPE: 0.00
BABY.TO balance_sheet (annual, 2024-12-31) — Raw Materials: 1728000.00
BABY.TO balance_sheet (quarterly, 2024-12-31) — Raw Materials: 1728000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Receivables: 1089000.00
BABY.TO income_statement (annual, 2024-12-31) — Reconciled Cost Of Revenue: 9135000.00
BABY.TO income_statement (annual, 2024-12-31) — Reconciled Depreciation: 336000.00
BABY.TO cash_flow (annual, 2024-12-31) — Repayment Of Debt: -228000.00
BABY.TO income_statement (annual, 2024-12-31) — Research And Development: 1169000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Restricted Cash: 296000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Retained Earnings: -79659000.00
BABY.TO income_statement (annual, 2024-12-31) — Salaries And Wages: 4146000.00
BABY.TO cash_flow (annual, 2024-12-31) — Sale Of PPE: 0.00
BABY.TO income_statement (annual, 2024-12-31) — Selling And Marketing Expense: 4639000.00
BABY.TO income_statement (annual, 2024-12-31) — Selling General And Administration: 10293000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Share Issued: 228854107.00
BABY.TO cash_flow (annual, 2024-12-31) — Short Term Debt Issuance: 0.00
BABY.TO cash_flow (annual, 2024-12-31) — Short Term Debt Payments: 0.00
BABY.TO income_statement (annual, 2024-12-31) — Special Income Charges: 0.00
BABY.TO cash_flow (annual, 2024-12-31) — Stock Based Compensation: 236000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Stockholders Equity: 1755000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Tangible Book Value: 1591000.00
BABY.TO income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
BABY.TO income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.00
BABY.TO balance_sheet (annual, 2024-12-31) — Total Assets: 7560000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Total Capitalization: 1755000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Total Debt: 874000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: 1755000.00
BABY.TO income_statement (annual, 2024-12-31) — Total Expenses: 22690000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 5805000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 717000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 0.00
BABY.TO income_statement (annual, 2024-12-31) — Total Unusual Items: 2678000.00
BABY.TO income_statement (annual, 2024-12-31) — Total Unusual Items Excluding Goodwill: 2678000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Work In Process: 132000.00
BABY.TO balance_sheet (quarterly, 2024-12-31) — Work In Process: 132000.00
BABY.TO balance_sheet (annual, 2024-12-31) — Working Capital: 1038000.00
BABY.TO income_statement (quarterly, 2025-03-31) — +Operating Expense: 2182000.00
BABY.TO income_statement (quarterly, 2025-03-31) — +Total Revenue: 2085000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 2083000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 941000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Basic Average Shares: 27072598.00
BABY.TO income_statement (quarterly, 2025-03-31) — Basic EPS: -0.13
BABY.TO cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 47000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 22000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Capital Stock: 75180000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 215000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 215000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Financing Activities: 1354000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Investing Activities: 352000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: -957000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Change In Account Payable: -668000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Change In Inventory: 853000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Change In Payable: -773000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Change In Payables And Accrued Expense: -773000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Change In Receivables: -67000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Change In Working Capital: 13000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Changes In Account Receivables: -118000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Changes In Cash: 749000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Common Stock: 75180000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: -427000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Common Stock Issuance: 503000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 1576000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Current Assets: 5850000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 22000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Current Debt: 1099000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 1121000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 6796000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 107000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Depreciation Amortization Depletion Income Statement: 107000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 107000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 107000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 27072598.00
BABY.TO income_statement (quarterly, 2025-03-31) — Diluted EPS: -0.13
BABY.TO income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: -3435000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Dueto Related Parties Current: 21000.00
BABY.TO income_statement (quarterly, 2025-03-31) — EBIT: -3328000.00
BABY.TO income_statement (quarterly, 2025-03-31) — EBITDA: -3221000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Effect Of Exchange Rate Changes: -581000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — End Cash Position: 215000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: 1354000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Free Cash Flow: -957000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Gain Loss On Investment Securities: 1615000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Gain On Sale Of Security: -968000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Gains Losses Not Affecting Retained Earnings: -458000.00
BABY.TO income_statement (quarterly, 2025-03-31) — General And Administrative Expense: 1057000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 156000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Gross PPE: 363000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Gross Profit: 509000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Interest Expense: 107000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 107000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Interest Income: 3000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Interest Income Non Operating: 3000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Interest Received Cfo: 0.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Inventory: 4261000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Invested Capital: 672000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: 352000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Issuance Of Capital Stock: 503000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Issuance Of Debt: 964000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Line Of Credit: 0.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Long Term Debt Payments: -113000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Net Common Stock Issuance: 503000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Net Debt: 884000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Net Income: -3435000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: -3435000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: -3435000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: -3435000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: -3435000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: -3435000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: -3435000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Net Interest Income: -104000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Net Investment Purchase And Sale: 0.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Net Issuance Payments Of Debt: 851000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Net Long Term Debt Issuance: -113000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -104000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Net Other Investing Changes: 279000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Net PPE: 363000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Net PPE Purchase And Sale: 73000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Net Short Term Debt Issuance: 964000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: -583000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Normalized EBITDA: -2253000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Normalized Income: -2467000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: -957000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Operating Gains Losses: 1615000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Operating Income: -1673000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Operating Revenue: 2085000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 311881090.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Other Current Borrowings: 1099000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 1659000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Other Equity Adjustments: -458000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Other Equity Interest: 7945000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Other Gand A: 175000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Other Income Expense: -1658000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Other Non Cash Items: 732000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: -690000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 431000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Other Payable: 1912000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Other Properties: 363000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Other Receivables: 416000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Payables: 4016000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Payables And Accrued Expenses: 4016000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Pretax Income: -3435000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Proceeds From Stock Option Exercised: 0.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Purchase Of PPE: 0.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Receivables: 1357000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 1576000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 107000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Repayment Of Debt: -113000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Research And Development: 24000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 17000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Retained Earnings: -83094000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Salaries And Wages: 882000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Sale Of PPE: 73000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Selling And Marketing Expense: 563000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Selling General And Administration: 1620000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Share Issued: 311881090.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Short Term Debt Issuance: 964000.00
BABY.TO cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 11000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: -427000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: -583000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
BABY.TO income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Total Assets: 6369000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Total Capitalization: -427000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Total Debt: 1121000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: -427000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Total Expenses: 3758000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 6796000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 519000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 0.00
BABY.TO income_statement (quarterly, 2025-03-31) — Total Unusual Items: -968000.00
BABY.TO income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: -968000.00
BABY.TO balance_sheet (quarterly, 2025-03-31) — Working Capital: -946000.00
BABY.TO income_statement (quarterly, 2025-06-30) — +Operating Expense: 1336000.00
BABY.TO income_statement (quarterly, 2025-06-30) — +Total Revenue: 1500000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 1647000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Accounts Receivable: 763000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Basic Average Shares: 304502175.00
BABY.TO income_statement (quarterly, 2025-06-30) — Basic EPS: -0.04
BABY.TO cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 215000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Capital Lease Obligations: 32000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Capital Stock: 76140000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 69000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 69000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Financing Activities: 472000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Investing Activities: -1000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: -2273000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Change In Account Payable: -421000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Change In Inventory: 822000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Change In Payable: -448000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Change In Payables And Accrued Expense: -448000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Change In Receivables: -714000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Change In Working Capital: -340000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Changes In Account Receivables: -25000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Changes In Cash: -1802000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Common Stock: 76140000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: -691000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Common Stock Issuance: 0.00
BABY.TO income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 1555000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Current Assets: 4377000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Current Capital Lease Obligation: 32000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Current Debt: 886000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Current Debt And Capital Lease Obligation: 918000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 5511000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Depreciation Amortization Depletion: 77000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Depreciation Amortization Depletion Income Statement: 77000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Depreciation And Amortization: 77000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 77000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 304502175.00
BABY.TO income_statement (quarterly, 2025-06-30) — Diluted EPS: -0.04
BABY.TO income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: -1438000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Dueto Related Parties Current: 49000.00
BABY.TO income_statement (quarterly, 2025-06-30) — EBIT: -2987000.00
BABY.TO income_statement (quarterly, 2025-06-30) — EBITDA: -2910000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Effect Of Exchange Rate Changes: 1656000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — End Cash Position: 69000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: 472000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Free Cash Flow: -2273000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Gain Loss On Investment Securities: -641000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Gain On Sale Of Security: -1360000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Gains Losses Not Affecting Retained Earnings: -24000.00
BABY.TO income_statement (quarterly, 2025-06-30) — General And Administrative Expense: 651000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Goodwill And Other Intangible Assets: 155000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Gross PPE: 288000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Gross Profit: -55000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Interest Expense: 51000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 51000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Interest Income: 2000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Interest Income Non Operating: 2000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Inventory: 3268000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Invested Capital: 195000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Investing Cash Flow: -1000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Issuance Of Capital Stock: 0.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Issuance Of Debt: 304000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Line Of Credit: 0.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Long Term Debt Payments: 10000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Net Common Stock Issuance: 0.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Net Debt: 817000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Net Income: -1438000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: -1438000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: -3038000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: -1438000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: -1438000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: -1665000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: -3038000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Net Interest Income: -49000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Net Investment Purchase And Sale: 0.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Net Issuance Payments Of Debt: 472000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Net Long Term Debt Issuance: 1278000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -49000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Net Other Investing Changes: -1000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Net PPE: 288000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Net PPE Purchase And Sale: 0.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Net Short Term Debt Issuance: -806000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: -846000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Normalized EBITDA: -1550000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Normalized Income: -78000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: -2273000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Operating Gains Losses: -641000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Operating Income: -1391000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Operating Revenue: 1500000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 374114284.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Other Current Borrowings: 886000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Other Current Liabilities: 1018000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Other Equity Adjustments: -24000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Other Equity Interest: 7952000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Other Gand A: 78000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Other Income Expense: -1598000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Other Non Cash Items: 289000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: -238000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 162000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Other Payable: 1879000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Other Properties: 288000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Other Receivables: 259000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Payables: 3575000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 3575000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Pretax Income: -3038000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Proceeds From Stock Option Exercised: 0.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Purchase Of PPE: 0.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Receivables: 1022000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 1555000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 77000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Repayment Of Debt: 10000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Research And Development: 0.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Restricted Cash: 18000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Retained Earnings: -84759000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Salaries And Wages: 573000.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Sale Of PPE: 0.00
BABY.TO income_statement (quarterly, 2025-06-30) — Selling And Marketing Expense: 446000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Selling General And Administration: 1097000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Share Issued: 374114284.00
BABY.TO cash_flow (quarterly, 2025-06-30) — Stock Based Compensation: 7000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: -691000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: -846000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
BABY.TO income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Total Assets: 4820000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Total Capitalization: -691000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Total Debt: 918000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: -691000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Total Expenses: 2891000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 5511000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 443000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 0.00
BABY.TO income_statement (quarterly, 2025-06-30) — Total Unusual Items: -1360000.00
BABY.TO income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: -1360000.00
BABY.TO balance_sheet (quarterly, 2025-06-30) — Working Capital: -1134000.00
BABY.TO income_statement (quarterly, 2025-09-30) — +Operating Expense: 1148000.00
BABY.TO income_statement (quarterly, 2025-09-30) — +Total Revenue: 1664000.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 1530000.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 825000.00
BABY.TO income_statement (quarterly, 2025-09-30) — Basic Average Shares: 37411428.00
BABY.TO income_statement (quarterly, 2025-09-30) — Basic EPS: -0.02
BABY.TO cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 69000.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 0.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Capital Stock: 76140000.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 72000.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 72000.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: -203000.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Investing Activities: -1000.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: 970000.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Change In Account Payable: -185000.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Change In Inventory: 530000.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Change In Payable: -77000.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: -77000.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Change In Receivables: 1014000.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Change In Working Capital: 1467000.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Changes In Account Receivables: 150000.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Changes In Cash: 766000.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Common Stock: 76140000.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: -1370000.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Common Stock Issuance: 0.00
BABY.TO income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 1093000.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Current Assets: 3967000.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 0.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Current Debt: 924000.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 924000.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 5763000.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Depreciation Amortization Depletion: 33000.00
BABY.TO income_statement (quarterly, 2025-09-30) — Depreciation Amortization Depletion Income Statement: 33000.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 33000.00
BABY.TO income_statement (quarterly, 2025-09-30) — Depreciation And Amortization In Income Statement: 33000.00
BABY.TO income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 37411428.00
BABY.TO income_statement (quarterly, 2025-09-30) — Diluted EPS: -0.02
BABY.TO income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: -602000.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Dueto Related Parties Current: 49000.00
BABY.TO income_statement (quarterly, 2025-09-30) — EBIT: -546000.00
BABY.TO income_statement (quarterly, 2025-09-30) — EBITDA: -513000.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Effect Of Exchange Rate Changes: -763000.00
BABY.TO cash_flow (quarterly, 2025-09-30) — End Cash Position: 72000.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: -203000.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Free Cash Flow: 970000.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Gain Loss On Investment Securities: 192000.00
BABY.TO income_statement (quarterly, 2025-09-30) — Gain On Sale Of Security: -221000.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Gains Losses Not Affecting Retained Earnings: -166000.00
BABY.TO income_statement (quarterly, 2025-09-30) — General And Administrative Expense: 648000.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 154000.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Gross PPE: 272000.00
BABY.TO income_statement (quarterly, 2025-09-30) — Gross Profit: 571000.00
BABY.TO income_statement (quarterly, 2025-09-30) — Interest Expense: 56000.00
BABY.TO income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 56000.00
BABY.TO income_statement (quarterly, 2025-09-30) — Interest Income: 0.00
BABY.TO income_statement (quarterly, 2025-09-30) — Interest Income Non Operating: 0.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Inventory: 2788000.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Invested Capital: -446000.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: -1000.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Issuance Of Capital Stock: 0.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Issuance Of Debt: 0.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Line Of Credit: 0.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Long Term Debt Payments: 0.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Net Common Stock Issuance: 0.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Net Debt: 852000.00
BABY.TO income_statement (quarterly, 2025-09-30) — Net Income: -602000.00
BABY.TO income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: -602000.00
BABY.TO income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: -602000.00
BABY.TO income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: -602000.00
BABY.TO income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: -602000.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: -542000.00
BABY.TO income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: -602000.00
BABY.TO income_statement (quarterly, 2025-09-30) — Net Interest Income: -56000.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Net Investment Purchase And Sale: 0.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Net Issuance Payments Of Debt: -203000.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Net Long Term Debt Issuance: -1268000.00
BABY.TO income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: -56000.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Net Other Investing Changes: -1000.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Net PPE: 272000.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Net PPE Purchase And Sale: 0.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Net Short Term Debt Issuance: 1065000.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: -1524000.00
BABY.TO income_statement (quarterly, 2025-09-30) — Normalized EBITDA: -292000.00
BABY.TO income_statement (quarterly, 2025-09-30) — Normalized Income: -381000.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: 970000.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Operating Gains Losses: 192000.00
BABY.TO income_statement (quarterly, 2025-09-30) — Operating Income: -577000.00
BABY.TO income_statement (quarterly, 2025-09-30) — Operating Revenue: 1664000.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 37411428.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Other Current Borrowings: 924000.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 1210000.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Other Equity Adjustments: -166000.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Other Equity Interest: 7957000.00
BABY.TO income_statement (quarterly, 2025-09-30) — Other Gand A: 101000.00
BABY.TO income_statement (quarterly, 2025-09-30) — Other Income Expense: 31000.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Other Non Cash Items: -364000.00
BABY.TO income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: 252000.00
BABY.TO income_statement (quarterly, 2025-09-30) — Other Operating Expenses: 162000.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Other Payable: 2050000.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Other Properties: 272000.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Other Receivables: 263000.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Payables: 3629000.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 3629000.00
BABY.TO income_statement (quarterly, 2025-09-30) — Pretax Income: -602000.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Proceeds From Stock Option Exercised: 0.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Purchase Of PPE: 0.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Receivables: 1088000.00
BABY.TO income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 1093000.00
BABY.TO income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 33000.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Repayment Of Debt: -45000.00
BABY.TO income_statement (quarterly, 2025-09-30) — Research And Development: 0.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Restricted Cash: 19000.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Retained Earnings: -85301000.00
BABY.TO income_statement (quarterly, 2025-09-30) — Salaries And Wages: 547000.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Sale Of PPE: 0.00
BABY.TO income_statement (quarterly, 2025-09-30) — Selling And Marketing Expense: 305000.00
BABY.TO income_statement (quarterly, 2025-09-30) — Selling General And Administration: 953000.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Share Issued: 37411428.00
BABY.TO cash_flow (quarterly, 2025-09-30) — Stock Based Compensation: 5000.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: -1370000.00
BABY.TO balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: -1524000.00
BABY.TO income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
BABY.TO income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.00